

Index

- [¹¹C]Carfentanil, 105
- [¹¹C]PK11195, 105
- [¹¹C]Raclopride, 102
- [¹¹C]flumazenil, 104
- [¹¹C]β-CFT, 101
- [¹²³I]iodobenzamide, 102
- [¹²³I]iomazenil, 104
- [¹²⁴I]FIAU, 185, 187, 188, 195
- [¹⁸F]FDG, 171
- [¹⁸F]FDG PET, 171–174
- [¹⁸F]FDG PET imaging, 172, 175
- [¹⁸F]FDG PET-CT imaging, 173
- [¹⁸F]FDOPA, 101
- [¹⁸F]FES, 98
- [¹⁸F]FHBG, 184, 185, 187, 188
- [¹⁸F]altanserin, 104
- β-galactosidase, 49
- β-glucuronidase, 49
- σ₂-R targeting ligands, 97
- ¹¹¹In-oxine, 288
- ¹¹¹In-oxine labeling, 287
- ¹⁸F-FDG, 286
- ¹⁸F-annexin V, 266
- ⁶⁴Cu-pyruvaldehyde-bis(N⁴-methylthiosemicarbazone), 287
- ^{99m}Tc-hexamethazine, 287
- ^{99m}Tc-Labeled annexin, 263
- ^{99m}Tc-N₂S₂-rh-annexin, 263
- ¹⁹F, 315
- β-galactosidase activity, 11
- 17-AAG, 210

- Activatable Contrast Agents, 42
- Acycloguanosine derivatives, 282
- Adrenergic system
 - α-receptors, 107
 - β-receptors, 107, 108

- Affinity selection, 148
- Amino acids transporters, 141
- Amplifying the fluorescence, 11
- Androgen
 - ablation therapy, 99, 100
- Angiogenesis, 317, 323
- Annexin V, 261
 - binding of annexin V, 261
- Annexin V-conjugated quantum dots, 267
- Annexin V-indocyanine fluorophore, 267
- Anti-p185^{HER2} minibodies, 177
- Antigen, 13, 18–20, 22, 146
- Antisense oligonucleotides, 29, 30
- AnxCLIO-Cy5.5, 267
- Apoptosis, 260
- Apoptosomes, 260
- Arthritis, 5

- BCR-ABL oncogene, 287
- Benzodiazepine
 - central receptor, 104
 - peripheral receptor, 105
- Bi-directional transcriptional approach, 295
- Bicistronic approaches, 295
- Biodistribution, 14, 17, 26, 30
- Bioluminescence, 170, 193, 203
- Bioluminescence imaging (BLI), 199, 202, 204, 205
- Bioluminescence reporter genes, 188
- Biomarker, 146, 171, 205, 210
- Biotin-labeled annexin V, 267
- Biotinylated phage, 156, 157
- Biphenyl, 50
- Blood oxygenation, 48
- Bone marrow-derived cells, 201
- Brain neuroreceptors and neurotransmitters, 100

- Ca-sensing, 46
- Calcium-sensing, 45
- Carcinoembryonic antigen (CEA) promoter, 293
- Cardiac infarction, 307
- Caspase activity, 8
- Caspase-3-specific binding peptides, 268
- Caspases, 137, 260
- Cathepsin-B, 5
- Cathepsins, 136
- Cavitation, 226–228, 230–233, 235, 237, 239
- Cell tracking, 305
- Cell trafficking, 278, 286, 308
- Cell-based therapy, 306
- CH₂
 - and CH₃, 268
- Cine MRI, 247
- Combinatorial chemistry, 146
- Contrast agent, 252
- Coordination number, 40
- Correlation time, 39
- Cyclodextrins, 41
- Cysteine or serine proteases, 5
- Cytosine deaminase, 280

- D2 receptor, 19
- Dendritic cell, 306, 316, 318
- Deoxyhemoglobin, 48
- Dequenching, 5
- Diffusion, 270
- Diffusion-weighted MR imaging, 269
- Direct, 167
- Direct imaging, 175
- Direct molecular imaging, 211
- Dopamine, 100–102
 - receptors, 101, 102
 - transporter, 101
- Dopamine 2 receptor (D2R), 280
- Dopamine 2 receptor (hD2R), 284
- Dual-promoter approaches, 295
- Dye, 310

- E-selectin, 52
- ED-B domain, 325
- EGFP, 186
- eGFP, 180, 191
- Endothelial progenitor cells, 288
- Enzyme, 311
- Enzyme-sensitive MR Contrast Agents, 49
- Estrogen receptor ligand-binding domain (ERL), 286
- Eu (III), 48

- FDG, 135, 138–140
- FDG PET, 171, 182, 210, 286, 292
- FEAU (2'-fluoro-2'-deoxyarabinofuranosyl-5-ethyluracil), 282
- Ferumoxides-poly-L-lysine, 288
- FHBG, 345, 347
- FHBG; 9-[4-fluoro-3-(hydromethyl) butyl] guanine), 282
- FIAU, 183, 346, 347
- FIAU (5-iodo-2'-fluoro-2'-deoxy-1-β-D-arabino-furanosyl-uracil), 282
- Fibronectin, 325
- Firefly, 188
- FLuc, 199
- Fluorescein isothiocyanate, 267
- Fluorescence, 193, 203
- Fluorescence imaging, 190
- Fluorescence reporter imaging, 190
- Fluorescence resonance energy transfer, 4
- Fluorescent protein-based reporter, 189
- Fluorescent proteins, 190, 211
- Fluorothymidine, 134
- Flutamide, 100
- Folate
 - conjugated tracers, 96
 - receptor imaging, 96
- Folate receptor, 94
- FPCV; fluoropenciclovir, 282
- Fusion approaches, 295
- Fusion reporter gene, 285

- Gadolinium, 38ff, 135, 175, 315
- Galactosidase, 135
- Gaussia, 188
- Gd chelating compounds, 38
- Gd-DOTA, 46
- Gene therapy, 14, 15, 18, 24, 226, 233, 235, 237, 341–343, 345–348, 350–353
- Gene transfer, 14, 18, 19, 24, 28
- GFP, 189, 310, 311
- Glioma, 341–343, 345, 348–353
- Glycosylation approach, 330
- Green fluorescent protein (GFP), 279
- GRP78 promoter, 293

- Heart failure, 249
- Heart function, 246
- Herpes simplex virus type 1 thymidine kinase (HSV1-tk), 280
- HIF-1α, 171
- HIF-1, 193–197
- HIV-Tat, 313
- hNET, 180, 211
- hNIS, 180, 186, 211

- HSP90, 210
hSSSTR2, 180
HSV thymidine kinase, 15, 17
HSV1-tk, 180, 182, 183, 185, 187, 188, 191, 208
HSV1-tk expression, 185, 194
HSV1-tk reporter, 182
HSV1-tk reporter gene, 200
HSV1-tk/eGFP, 192, 194
HSV1-TK/GFP, 196
HSV1-tk/GFP, 199
Human norepinephrine transporter, 286
Hydrazino nicotinamide, 263
Hydroxytyramide, 51
Hyperthermia, 233, 237, 238
- Imaging, 66, 67, 69, 74, 83, 167, 171, 193, 201, 205, 210
Imaging adoptive therapies, 198
Imaging modalities, 170
Imaging oncogenesis, 203
Imaging purposes, folic acid, 96
Imaging technologies, 169
Indirect imaging strategies, 167, 179
Infarction, 309, 317
Inflammatory plaque, 6
Inhibitor of DNA methyltransferase enzymes, 292
Inhibitor of histone deacetylase enzymes, 292
Inner coordination sphere, 39
Integrin $\alpha\beta 3$, 329
Interleukin-10, 290
Internal ribosomal entry site (IRES), 290, 295
Ion-selective agents, 45
Ischemia, 318
- Kinases, 134
- Leukocyte, 312
Lipid proton MR spectroscopy, 268
Liposomes, 45, 315
Luciferase, 191, 192, 204, 211, 279
Luciferase reporter gene, 202
Luciferase/GFP, 201
Lymph node, 312
Lymphocyte, 198, 306, 309, 316
- Macrophageous, 312
Magic angle spinning, 269
Magnetic resonance, 170
Magnetic resonance imaging (MR, MRI), 37ff, 135, 225, 226, 233, 234, 237–239, 245ff, 305ff, 348
Magnetic resonance spectroscopy (MRS), 245, 253, 259
Magneto-optical probe, 10
Matrix-metalloproteinase-2, 5
Matrix-metalloproteinases, 5, 136, 324, 328
MDR, 140
Mercaptoacetyltryglycine, 267
Metastasis, 146
MicroPET, 196, 200–203, 209
MMP, 137
Mn-porphyrin, 48
Molecular imaging, 94, 146, 168, 277, 278
 of brain neurotransmitters, 100–106
 of heart and lung neuroreceptors, 106, 107, 109
 of tumor receptors, 94, 96–100
Monitoring cell trafficking, 287
Monocyte trafficking, 286
Mouse, 245
Mouse models, 201, 202
MR contrast agents, 226, 234, 239
MR imaging, 178, 211
MRI, 245
mTOR depletion, 171
mTOR inhibitors, 172
Multimerization concept, 332
Multimers, 61, 80–82, 84
Multimodal probes, 11
Muscarinic acetylcholine receptor, 109
Mutant HSV1-tk gene, HSV1-sr39tk, 282
Myeloperoxidase, 52
Myocardial infarction, 246
- Nanoparticle/MR imaging, 178
Nanoparticles, 10
Negative hill effect, 266
NFAT-mediated activation, 201
Non-invasive imaging, 198
Norepinephrine transporter, 24, 27
Nuclear medicine, 308
- Oligomerization, 51
Oligonucleotide, 9ff, 29ff, 175
Oligonucleotide-based small, activatable optical probes, 9
Opioid
 δ -receptor, 106
 κ -receptor, 106
 μ -receptor, 105, 106
Optical, 170, 188
Optical imaging, 310
- Pancreatic islet graft survival, 290
Paramagnetic center, 45

- Parkinson disease, 307
 Pax8, 23
 Peptides, 61–63, 65, 66, 69, 72, 73, 80
 Perfusion, 134, 196, 245ff, 246, 289, 348
 Peroxidase, 51
 PET, 187, 193, 201, 308
 PET images, 196
 PET imaging, 177, 200, 201, 212
 pH responsive arm, 43
 pH-induced change, 42
 pH-responsive, 44
 pH-sensitive contrast agent, 43
 Phage display, 63ff, 146ff
 - Analysis techniques for selected phage clones, 149
 - Selection technique, 149
 Phage display cancer targets
 - Cell specific peptides, 150, 153, 154
 - Cell surface carbohydrates and lectins, 150, 151
 - Cell surface receptors, 149, 150, 154, 156–158
 - Integrins, 150, 152, 156, 157
 - Metalloproteases, 150, 151, 154
 Pharmacodynamics of HER2 degradation, 210
 Pinocytic pathway, 263
 Polyarginine, 11
 Polyethylene glycol (PEG) conjugation, 330
 Polyionic complex, 44
 Polymers, 61, 80–82
 Positron emission tomography (PET), 278
 Progenitor cell, 306, 309, 311, 312, 316, 317
 Progesterone receptor, 99
 Promoter, 13, 19, 21–24
 Prostate specific antigen (PSA) promoter, 293
 Proteases, 136
 Protein-protein interaction, 14, 20, 22, 23
 Proteolytic activation, 4
 Proton spectroscopy, 269
 Pyrimidine nucleoside derivatives, 282
- Quantum dot, 310
 Quenching, 4
- Radiation force, 230, 239
 Radiation therapy planning, 174
 Radiolabeling, 62, 63, 65–68
 Radiolabelled antibodies, 175
 Radiolabelled probe, 180, 182
 Radiolabelled VEGF, 326
 Radiolabelling anti-CEA minibodies, 176
 Radionuclide, 170
 - for PET, 94
 - for SPECT, 94
 Radionuclide-based imaging, 197
 Rat brain, 318
 Receptors, 13, 14, 18, 19, 62, 66, 71, 72, 76, 78, 79
 Recombinant antibody fragments, 149
 Regional blood volume, 251
 Relaxivity, 39ff
 Renilla, 188
 Reporter, 180, 188
 Reporter gene, 13, 17–24, 27, 168, 179, 186, 279
 Reporter gene HSV1-tk, 195
 Reporter gene imaging, 179, 187, 193, 211, 212
 Reporter gene/probe, 279
 Reporter imaging, 204
 Reporter probe, 280
 RFP, 311
 RGD-sequence, 329
- Scintigraphy, 17ff, 74, 98, 186, 293, 305, 308, 309
 SER¹A receptors, 103
 SER receptors, 102
 SER transporter, 102
 Serotonin, 52, 102
 - receptors, 101–103
 - transporter, 101
 Shrinkage necrosis, 260
 Sigma receptor, 96
 - α -tracers, 97
 - β -tracers, 97, 98
 - σ_1 - and σ_2 -sub-types, 96, 97
 - σ_2 -tracers, 97
 Signal-to-noise, 3
 Smart probes, 4
 Sodium iodide symporter (NIS), 140, 185, 280, 285
 Sodium iodide transporter, 18
 Somatostatin, 280
 Somatostatin receptor, 19
 Somatostatin receptor imaging, 284
 SPECT, 308
 SPIO, 178, 305, 312, 314
 Stain, 261
 Stearase, 50
 Stem cell, 318
 Stress-inducible chaperone protein, GRP78, 293
 Stroke, 318
 Suicide gene, 238, 289, 296
 Suicide gene therapy, 14
 Superparamagnetic iron oxides, 10
 Superparamagnetic nanoparticles, 179

- Supramolecular adduct, 41
- Supramolecular assemblies, 41
- Supramolecular systems, 47
- Surrogate, 167
- Synaptotagmin I, 267

- T-cell, 178, 198ff, 287, 306ff, 316
- T-cell activation, 200
- T-cell therapy, 212
- T-lymphocytes, 199
- Target oligonucleotide sequence, 9
- Temperature mapping, 226, 237–239
- Temperature monitoring, 47
- Terpyridine, 47
- Thrombin activatable fibrinolysis inhibitor, 50
- Thyroid transcription factor, 23
- Thyropoxidase, 23, 26
- Tissue-specific, 293
- Trafficking, 198, 199
- Transfection, 229, 231, 235–237
- Transfection agent, 315
- Transgene, 226, 235–239
- Transgenic mouse model, 249
- Translate strategies, 295
- Transporter, 13, 16, 19, 28, 137, 185
- Treatment, 172, 204, 206, 209
- Triple-reporter constructs, 193
- TRODAT-1, 101
- TSA, 292

- Tumor-selective promoters (TSPs), 293
- Tumorigenesis, 146
- Tunel, 261
- Two vector administration approach, 295
- Two-step transcriptional amplification (TSTA), 293

- Ultrasound, 226–232, 235–239
- Ultrasound contrast agents, 225, 226, 230, 233, 239
- USPIO, 312–314

- V117, 265
- V128, 265
- VEGF, 323ff, 326
- Vesicular monoamine transporter, 101
- Viral thymidine kinases, 211
- Viral vectors, 15, 24, 186, 212, 293, 341
- VSOP, 312

- Wall motion, 250
- Water exchange rate, 40
- WAY-100635, 103
- Wild-type herpes simplex virus type 1 thymidine kinase (HSV1-tk), 282

- Yb (III) chelate, 48

- Zn (II)-sensing, 46